The $200M upfront payment provides immediate liquidity but is offset by a contingent refund obligation tied to milestones. Monitor FMC's next earnings call for details on the Rimisoxafen development timeline and milestone probability. The stock has been under severe pressure (market cap ~$1.4B, historical T+20 alpha -15.9% on prior reports) — this deal alone is unlikely to reverse the trend without evidence of broader operational improvement.
Price Chart
Executive Summary
FMC entered Amendment No. 7 to its credit agreement to facilitate a $200M supply and license deal with Corteva Agriscience for the Rimisoxafen molecule. The amendment permits Corteva to take a first-priority lien on the related IP and releases that IP from the lenders' collateral pool, with a contingent refund obligation of up to $200M if milestones are not met. This is a routine credit-agreement amendment enabling a non-core asset monetization — no new debt is created, and the existing credit facility terms remain unchanged.
Key Financial Metrics
Key Facts
- FMC will receive a $200M upfront payment from Corteva for a license to Rimisoxafen-related IP.
- The payment is subject to a contingent refund obligation of up to $200M if certain milestones are not achieved.
- Corteva will receive a first-priority security interest in the Rimi IP to secure the refund obligation.
- The credit agreement amendment releases the Rimi IP from the lenders' collateral pool and permits the Corteva lien.
- No new debt is created; the existing credit facility's total capacity and terms remain unchanged.
- The amendment was approved by the Required Lenders and became effective June 16, 2026.
Financial Impact
FMC receives $200M upfront from Corteva, with a contingent refund obligation of up to $200M. No new debt or dilution.
Risk Factors
- Contingent refund obligation of up to $200M if milestones are not achieved, creating potential future cash outflow.
- Loss of collateral coverage for lenders on the Rimi IP could increase borrowing costs in future amendments.
- The deal does not address FMC's underlying operational or financial challenges that have driven recent stock declines.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-279416 |
| Document: d123428d8k.htm | 0001193125-26-279416 |
| Document: 0001193125-26-279416-index-headers.html | 0001193125-26-279416 |
| Document: 0001193125-26-279416-index.html | 0001193125-26-279416 |
| Document: 0001193125-26-279416.txt | 0001193125-26-279416 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jul 23, 2026 10w ago | Press Release | $11.30 $11.02 | ▼ −2.48% | ▼ −6.10% | $8.52 (−24.56%) |
Jul 1, 2026 13w ago | 8-K | $10.95 $10.01 | ▼ −8.58% | ▼ −6.40% | $8.52 (−22.15%) |
Jun 23, 2026 14w ago | 8-K | $11.32 $11.78 | ▲ +4.06% | ▲ +2.13% | $8.52 (−24.69%) |
Jun 12, 2026 16w ago | Institutional Cluster | $11.85 $10.91 | ▼ −7.93% | ▼ −9.71% | $8.52 (−28.06%) |
Jun 5, 2026 16w ago | 8-K | $11.10 $11.38 | ▲ +2.52% | ▲ +0.89% | $8.52 (−23.20%) |
May 21, 2026 19w ago | 8-K | $13.11 $11.13 | ▼ −15.12% | ▼ −13.71% | $8.52 (−34.97%) |
May 19, 2026 19w ago | 8-K | $12.76 $11.98 | ▼ −6.11% | ▼ −7.10% | $8.52 (−33.19%) |
Apr 29, 2026 22w ago | 8-K | $15.38 $13.57 | ▼ −11.77% | ▼ −16.74% | $8.52 (−44.57%) |
Apr 29, 2026 22w ago | 8-K | $15.38 $13.57 | ▼ −11.77% | ▼ −16.74% | $8.52 (−44.57%) |
Apr 27, 2026 22w ago | DEFA14A | $15.56 $12.98 | ▼ −16.58% | ▼ −21.54% | $8.52 (−45.21%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access